Published on
February 13, 2012
- 20:19 GMT
TCT Receives Patent on Small Molecule for Treating Multiple Cancer Types
/EINPresswire.com/ SANTA ROSA, CA (2/14/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its Nucleophosmin 1 (NPM1) inhibitor, NSC348884, received the U.S. Designation of Patent Number 8,063,089. The patent claims allow for a method for …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...
